European Heart Journal Advance Access originally published online on October 14, 2007
European Heart Journal 2007 28(21):2578-2582; doi:10.1093/eurheartj/ehm424
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions
1 HELIOS Heart Center Siegburg, Siegburg, Germany
2 Wessex Cardiothoracic Centre, Southampton University Hospital, Southampton, UK
3 Ospedali Riuniti di Bergamo, Bergamo, Italy
4 John Radcliffe Hospital, Oxford, UK
5 Jan Pawel II Hospital, International Cardiology Clinic, Krakow, Poland
6 Ospedale San Raffaele, Milano, Italy
7 Skejby Sygehus Hospital, Aarhus, Denmark
8 Krankenhaus der Barmherzigen Brüder, Trier, Germany
9 Clinique Pasteur, Toulouse, France
10 O.L.V. Hospital, Aalst, Belgium
11 Brigham and Women's Hospital, Boston, USA
12 Boston Scientific Corporation, Natick, USA
Received 21 February 2006; revised 9 August 2007; accepted 23 August 2007; online publish-ahead-of-print 14 October 2007.
* Corresponding author: Department of Cardiology/Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany. Tel: +49 2241 18 2322; fax: +49 2241 18 2451. E-mail address: grubee{at}aol.com
See page 2559 for the editorial comment on this article (doi:10.1093/eurheartj/ehl195)
Aims: Drug-eluting stents (DESs) have shown to be effective in reducing in-stent restenosis, although data relating to long-term experience in treating more complex lesion subsets are limited. In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting TAXUSTM MR stent in treatment of complex lesion subsets, we evaluated the 2-year follow-up of TAXUS VI.
Method and results: TAXUS VI was a randomized multi-centre study enrolling 446 patients with complex lesions, including small vessels in 28% of patients and a mean lesion length of 20.6 mm. At 9-month follow-up, the use of the TAXUS MR stent was highly effective, resulting in a significant 53% reduction of the target vessel revascularization (TVR) rate (primary endpoint) from 19.4% in the control group to 9.1% in the TAXUS group (P = 0.0027). Clinical follow-up at 2 years post-stenting was available in 98.6% of the TAXUS group and 95.6% of the control group. The incidence of major adverse cardiac event at 1- and 2-year follow-up was 16.4% and 21.3% in the TAXUS group when compared with 22.5 and 25.1% in the control group, respectively. A significant difference in TVR was maintained at 2-year follow-up (TAXUS 13.9%; control 21.9%; P = 0.0335). The cumulative 1- and 2-year survival rates free from TVR were, respectively, 91.7 and 90.3% in the TAXUS group vs. 80.0 and 79.0% in the control group (log-rank P < 0.001). The number of patients required to be treated with a TAXUS stent to prevent one re-percutaneous coronary intervention at 2 years was 12.5.
Conclusion: Treatment of complex coronary lesions with the polymer-based MR paclitaxel-eluting TAXUS MR stent is associated with a sustained clinical benefit and low rates of TVR up to 2 years after device implantation.
Key Words: Paclitaxel • Stent • Follow-up • Coronary artery disease
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Drug-eluting stents: effective and safe for every patient and every lesion?
- Uwe Zeymer and Ralf Zahn
EHJ 2007 28: 2559-2560.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  M. A.M. Beijk, M. Klomp, N. J.W. Verouden, N. van Geloven, K. T. Koch, J. P.S. Henriques, J. Baan, M. M. Vis, E. Scheunhage, J. J. Piek, et al. GenousTM endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study Eur. Heart J., November 18, 2009; (2009) ehp476v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Silber, A. Colombo, A. P. Banning, K. Hauptmann, J. Drzewiecki, E. Grube, D. Dudek, and D. S. Baim Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions Circulation, October 13, 2009; 120(15): 1498 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Brodie, T. Stuckey, W. Downey, A. Humphrey, B. Bradshaw, C. Metzger, J. Hermiller, F. Krainin, S. Juk, B. Cheek, et al. Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 405 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Zeymer and R. Zahn Drug-eluting stents: effective and safe for every patient and every lesion? Eur. Heart J., November 1, 2007; 28(21): 2559 - 2560. [Full Text] [PDF]
|
|